Tyers Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Tyers Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$164K	Buy	7,632 +7,280	+2,068%	+$201K	0.01%	760
2019 Q2	$10K	Buy	+352	New	+$9.6K	﹤0.01%	980

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tyers Asset Management's BBIO Position: Q3 2019 in Review

Tyers Asset Management increased its BridgeBio Pharma (BBIO) stake by 2,068% in Q3 2019, buying an estimated $201K and bringing the position to 7,632 shares worth $164K. The position accounts for 0.01% of the portfolio, ranked #760.

Tyers Asset Management first reported a position in BBIO in Q2 2019 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BBIO as of Q3 2019.

Tyers Asset Management held 7,632 shares of BridgeBio Pharma worth $164K as of Q3 2019.
Tyers Asset Management bought 7,280 BridgeBio Pharma shares in Q3 2019, an estimated $201K.
BridgeBio Pharma made up 0.01% of Tyers Asset Management's portfolio in Q3 2019, its #760 holding.
Tyers Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 2 quarters since.
75 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.